Last reviewed · How we verify

Lopinavir-ritonavir (LPV-RTV)

National Institute of Allergy and Infectious Diseases (NIAID) · Phase 3 active Small molecule

Lopinavir-ritonavir (LPV-RTV) is a Protease inhibitor combination Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).

Lopinavir-ritonavir is a combination of two protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.

Lopinavir-ritonavir is a combination of two protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).

At a glance

Generic nameLopinavir-ritonavir (LPV-RTV)
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classProtease inhibitor combination
TargetHIV protease
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Lopinavir inhibits HIV protease, an enzyme essential for processing viral proteins into functional forms. Ritonavir is a potent protease inhibitor that also acts as a pharmacokinetic booster, inhibiting cytochrome P450 metabolism to increase lopinavir plasma concentrations. Together, they prevent the maturation of HIV virions, rendering newly produced viral particles non-infectious.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lopinavir-ritonavir (LPV-RTV)

What is Lopinavir-ritonavir (LPV-RTV)?

Lopinavir-ritonavir (LPV-RTV) is a Protease inhibitor combination drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).

How does Lopinavir-ritonavir (LPV-RTV) work?

Lopinavir-ritonavir is a combination of two protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.

What is Lopinavir-ritonavir (LPV-RTV) used for?

Lopinavir-ritonavir (LPV-RTV) is indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).

Who makes Lopinavir-ritonavir (LPV-RTV)?

Lopinavir-ritonavir (LPV-RTV) is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

What drug class is Lopinavir-ritonavir (LPV-RTV) in?

Lopinavir-ritonavir (LPV-RTV) belongs to the Protease inhibitor combination class. See all Protease inhibitor combination drugs at /class/protease-inhibitor-combination.

What development phase is Lopinavir-ritonavir (LPV-RTV) in?

Lopinavir-ritonavir (LPV-RTV) is in Phase 3.

What are the side effects of Lopinavir-ritonavir (LPV-RTV)?

Common side effects of Lopinavir-ritonavir (LPV-RTV) include Diarrhea, Nausea, Abdominal pain, Vomiting, Headache, Lipid abnormalities (elevated cholesterol/triglycerides).

What does Lopinavir-ritonavir (LPV-RTV) target?

Lopinavir-ritonavir (LPV-RTV) targets HIV protease and is a Protease inhibitor combination.

Related